Ventyx Biosciences, Inc. (VTYX)
NASDAQ: VTYX · Real-Time Price · USD
13.81
-0.03 (-0.22%)
At close: Jan 9, 2026, 4:00 PM EST
13.82
+0.01 (0.07%)
After-hours: Jan 9, 2026, 7:58 PM EST
Ventyx Biosciences Stock Forecast
Stock Price Forecast
The 6 analysts that cover Ventyx Biosciences stock have a consensus rating of "Hold" and an average price target of $13.5, which forecasts a -2.24% decrease in the stock price over the next year. The lowest target is $11 and the highest is $14.
Price Target: $13.5 (-2.24%)
Analyst Consensus: Hold
Analyst Ratings
The average analyst rating for Ventyx Biosciences stock is "Hold". This means that analysts believe this stock is likely to perform similarly to the overall market.
Recommendation Trends
| Rating | Aug '25 | Sep '25 | Oct '25 | Nov '25 | Dec '25 | Jan '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 1 | 1 | 1 | 3 | 3 | 1 |
| Buy | 2 | 2 | 1 | 2 | 2 | 0 |
| Hold | 1 | 1 | 1 | 0 | 0 | 6 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 4 | 4 | 3 | 5 | 5 | 7 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| Oppenheimer | Oppenheimer | Buy → Hold Downgrades n/a | Buy → Hold | Downgrades | n/a | n/a | Jan 8, 2026 |
| Wells Fargo | Wells Fargo | Buy → Hold Downgrades $14 | Buy → Hold | Downgrades | $14 | +1.38% | Jan 8, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy → Hold Downgrades $14 | Strong Buy → Hold | Downgrades | $14 | +1.38% | Jan 8, 2026 |
| UBS | UBS | Strong Buy → Hold Downgrades $20 → $14 | Strong Buy → Hold | Downgrades | $20 → $14 | +1.38% | Jan 8, 2026 |
| LifeSci Capital | LifeSci Capital | Buy → Hold Downgrades $14 | Buy → Hold | Downgrades | $14 | +1.38% | Jan 8, 2026 |
Financial Forecast
Revenue This Year
n/a
Revenue Next Year
n/a
EPS This Year
-1.48
from -1.97
EPS Next Year
-1.72
from -1.48
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | n/a | n/a | ||||
| Avg | n/a | n/a | ||||
| Low | n/a | n/a |
Revenue Growth
| Revenue Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
EPS Forecast
| EPS | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | -1.42 | -1.20 | ||||
| Avg | -1.48 | -1.72 | ||||
| Low | -1.54 | -2.21 |
EPS Growth
| EPS Growth | 2025 | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|---|
| High | - | - | ||||
| Avg | - | - | ||||
| Low | - | - |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.